Salim Shah

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. doi request reprint Drug discovery dilemma and Cura quartet collaboration
    Salim Shah
    Office of Planning and Enterprise Development, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC 20057, USA
    Drug Discov Today 14:1006-10. 2009
  2. ncbi request reprint Trans-repression of beta-catenin activity by nuclear receptors
    Salimuddin Shah
    The Lombardi Cancer Center and the Department of Oncology, Georgetown University School of Medicine, Washington, DC 20057, USA
    J Biol Chem 278:48137-45. 2003
  3. ncbi request reprint The molecular basis of vitamin D receptor and beta-catenin crossregulation
    Salimuddin Shah
    The Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Mol Cell 21:799-809. 2006
  4. ncbi request reprint Vitamin D and the regulation of Wnt/beta-catenin signaling and innate immunity in colorectal cancer
    Stephen Byers
    Lombardi Comprehensive Cancer Center, E415 Research Building, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA
    Nutr Rev 65:S118-20. 2007
  5. doi request reprint Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease
    Linda MacArthur
    Georgetown University Medical Center, Washington, DC, USA
    Expert Rev Neurother 13:685-93. 2013
  6. pmc Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription
    Liang Nian Song
    Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, D C 20007 2197, USA
    Mol Cell Biol 23:1674-87. 2003
  7. pmc Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines
    Marcy E Beildeck
    Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA
    PLoS ONE 4:e7872. 2009
  8. pmc Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease
    Liang Huang
    Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA
    Neurotherapeutics 10:840-51. 2013
  9. pmc Genomics and bioinformatics of Parkinson's disease
    Sonja W Scholz
    Department of Neuroscience, Georgetown University, Washington, DC, USA
    Cold Spring Harb Perspect Med 2:a009449. 2012

Collaborators

Detail Information

Publications9

  1. doi request reprint Drug discovery dilemma and Cura quartet collaboration
    Salim Shah
    Office of Planning and Enterprise Development, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC 20057, USA
    Drug Discov Today 14:1006-10. 2009
    ....
  2. ncbi request reprint Trans-repression of beta-catenin activity by nuclear receptors
    Salimuddin Shah
    The Lombardi Cancer Center and the Department of Oncology, Georgetown University School of Medicine, Washington, DC 20057, USA
    J Biol Chem 278:48137-45. 2003
    ....
  3. ncbi request reprint The molecular basis of vitamin D receptor and beta-catenin crossregulation
    Salimuddin Shah
    The Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Mol Cell 21:799-809. 2006
    ....
  4. ncbi request reprint Vitamin D and the regulation of Wnt/beta-catenin signaling and innate immunity in colorectal cancer
    Stephen Byers
    Lombardi Comprehensive Cancer Center, E415 Research Building, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA
    Nutr Rev 65:S118-20. 2007
  5. doi request reprint Network modeling to identify new mechanisms and therapeutic targets for Parkinson's disease
    Linda MacArthur
    Georgetown University Medical Center, Washington, DC, USA
    Expert Rev Neurother 13:685-93. 2013
    ..Network modeling may help develop testable hypotheses for neurodegenerative diseases and open up new avenues for therapeutic development...
  6. pmc Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription
    Liang Nian Song
    Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, D C 20007 2197, USA
    Mol Cell Biol 23:1674-87. 2003
    ..Taken together, the data show that beta-catenin can bind to the androgen receptor LBD and modulate the effects of the androgen receptor NTD and TIF2 on transcription...
  7. pmc Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines
    Marcy E Beildeck
    Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University School of Medicine, Washington, DC, USA
    PLoS ONE 4:e7872. 2009
    ..Here we identify TCF-4, a transcriptional regulator and beta-catenin binding partner as an indirect target of the VDR pathway...
  8. pmc Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease
    Liang Huang
    Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA
    Neurotherapeutics 10:840-51. 2013
    ..Taken together, these inducible LRRK2 cell lines are suitable reagents for LRRK2 functional studies, and the screening of potential LRRK2 therapeutics...
  9. pmc Genomics and bioinformatics of Parkinson's disease
    Sonja W Scholz
    Department of Neuroscience, Georgetown University, Washington, DC, USA
    Cold Spring Harb Perspect Med 2:a009449. 2012
    ..Herein we discuss how neurogenomics and bioinformatics are applied to dissect the nature of this complex disease with the overall aim of developing rational therapeutic interventions...